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Abstract  Inotropic  drugs  are  part  of  the  treatment  of  heart  failure;  however,  inotropic  treat-
ment has  been  largely  debated  due  to  the  increased  incidence  of  adverse  effects  and  increased
mortality.  Recently  levosimendan,  an  inotropic  positive  agent,  has  been  proved  to  be  effective
in acute  heart  failure,  reducing  the  mortality  and  improving  cardiac  and  renal  performance.  We
report the  case  of  a  75-year-old  woman  with  history  of  heart  and  renal  failure  and  hip  fracture.
Levosimendan  was  used  in  preoperative  preparation  as  an  adjuvant  therapy,  to  improve  cardiac
and renal  function  and  to  allow  surgery.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Levosimendana  como  tratamento  para  insuﬁciência  renal  aguda  associada  a  choque
cardiogênico  após  fratura  de  quadril
Resumo  Fármacos  inotrópicos  fazem  parte  do  tratamento  de  insuﬁciência  cardíaca;  no
entanto, o  tratamento  com  inotrópicos  tem  sido  amplamente  debatido  devido  ao  aumento
da incidência  de  efeitos  adversos  e  da  mortalidade.  Recentemente,  levosimendana,  um  agente
inotrópico  positivo,  vem  provado  ser  eﬁcaz  na  insuﬁciência  cardíaca  aguda,  reduzindo  a  mor-
talidade e  melhorando  o  desempenho  cardíaco  e  renal.  Relatamos  o  caso  de  uma  paciente  de
75 anos  de  idade,  com  história  de  insuﬁciência  cardíaca  e  renal  e  fratura  de  quadril.  Levosi-arac¸
ermitir  a  cirurgia.
 de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
a  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-mendana foi  usada  na  prep
func¸ão cardíaca  e  renal  e  p
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ntroduction
uring  perioperative  period  the  development  of  acute  heart
ailure  increases  morbidity  and  mortality.1 Cardiac  failure  is
n  important  public  health  problem;  its  incidence  amounts
o  6--10%  in  the  population  over  65  years.  Levosimendan
Simdax® --  Orionpharma)  is  a  recommended  treatment  for
cute  heart  failure.2 Its  mechanism  of  action  allows  for  an
ncrease  in  contractility3 and  a  reduction  in  both  preload
nd  afterload,  improving  stroke  volume  and  cardiac  out-
ut  without  adversely  affecting  diastolic  function.4,5 The
aemodynamic  positive  effects  of  levosimendan  induce  also
 positive  result  on  tissular  perfusion,  as  reported  when
he  drug  has  been  employed  in  treating  cardiogenic  shock
ssociated  with  renal  failure.6 Currently,  there  are  few  stud-
es  about  the  preoperative  use  of  levosimendan  in  patients
ndergoing  non-cardiac  surgical  procedures.7
We  report  the  case  of  a  patient  with  a  hip  fracture;
he  developed  acute  renal  failure  secondary  to  cardiogenic
hock  before  undergoing  surgery  for  fracture  reduction.  Lev-
simendan  was  introduced  in  the  treatment  with  the  aim  of
mproving  cardiac  and  renal  functions;  ﬁnally,  it  results  in  an
ffective  tool  for  weaning  the  patient  from  hemoﬁltration
efore  surgery.
ase description
 75-year-old  woman  with  history  of  hypertension,  chronic
trial  ﬁbrillation,  congestive  heart  failure  with  baseline  LVEF
f  30%,  an  episode  of  pulmonary  embolism  in  2004,  chronic
enal  failure  (baseline  creatinine  2.2  mg/mL),  obstructive
leep  apnea-syndrome  associated  with  morbid  obesity,  and
yslipidemia,  was  admitted  to  the  emergency  department
ecause  of  accidental  fall  with  pertrochanteric  fracture  of
he  right  femur.
During  admission  in  ward,  pending  surgery,  a  tach-
arrhythmia,  probably  associated  with  the  acute  anaemia,
rovoked  an  acute  cardiac  failure  that  presented  together
cute  renal  failure.  The  patient  was  subsequently  trans-
erred  to  the  Intensive  Care  Unit  (ICU).
Once  in  the  ICU,  the  patient  received  basic  monitoring
ECG,  pulsioximetry)  and  advanced  haemodynamic  moni-
oring,  using  central  venous  access  (right  internal  jugular
ein)  and  central  arterial  line  (left  femoral  artery)  and
mploying  LiDCOTM plus  system  (LiDCO  Ltd,  Cambridge,
K).  The  parameters  on  admission  in  ICU  were:  invasive
lood  pressure  90/60;  heart  rate  120  beats  per  minute
ECG  showed  atrial  ﬁbrillation);  SpO2 93%  (with  0.5  FiO2);
ardiac  index:  2.4  L/min/m2,  systemic  vascular  resistance
500  dynes  s/cm.5 The  patient  showed  oliguric  acute  renal
ailure  (serum  creatinine:  4.7  mg/dL;  urea:  155  mg/dL)  and
uid  overload  (positive  balance  of  1787  mL  in  the  last  24  h)
efractory  to  therapy  with  diuretics.  For  these  reasons  renal
eplacement  therapy  was  started  with  continuous  veno-
enous  hemoﬁltration  (CVVHF),  coupled  to  non-invasive
entilation:  Bi-level  Positive  Airway  Pressure  (BiPAP).
Persistent  haemodynamic  instability  and  hypotension
ere  treated  starting  vasopressor  therapy  with  nor-
pinephrine  at  doses  of  0.04  mcg/kg/min.  In  lack  of
mprovement,  a  trans-thoracic  echocardiography  was  per-
ormed,  which  diagnosed  systolic  and  diastolic  dysfunction
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ssociated  with  pulmonary  arterial  hypertension,  without
igns  of  recent  thromboembolism.
In order  to  optimize  the  patient  preoperatively  and
mprove  kidney  function,  it  was  decided  to  start  a  treat-
ent  with  levosimendan  at  0.05  mcg/kg/min,  avoiding  the
nduction  bolus  and  gradually  increasing  the  dose  up  to
.1  mcg/kg/min,  according  to  the  haemodynamic  response
nd  the  tolerance  of  the  patient.
Progressive  improvement  in  renal  function,  recovering
pontaneous  and  satisfactory  urine  output  and  improved
nalytical  values  allowed  suspending  renal  replacement
herapy  prior  to  surgery.
The  patient  underwent  surgery  on  day  17  of  admission,
nder  spinal  anaesthesia.  The  intervention  was  marked  by
igniﬁcant  blood  loss  that  required  intraoperative  transfu-
ion  of  3  units  of  packed  red  blood  cells  and  2  units  of  fresh
rozen  plasma,  and  postoperative  transfusion  of  4  units  of
acked  red  cells  and  2  units  of  fresh  frozen  plasma,  with-
ut  recording  any  dysfunction  in  cardiac  performance.  On
ay  24,  the  patient  was  discharged  to  the  ward  without  any
enal  replacement  therapy  or  vasoactive  treatment.
iscussion
ue  to  its  high  morbidity  and  mortality  in  the  periopera-
ive  period,  heart  failure  in  patients  undergoing  non-cardiac
urgery  should  be  identiﬁed  and  treated  at  an  early  stage  to
nsure  adequate  preoperative  optimization  and  to  achieve
etter  haemodynamic  conditions  prior  to  surgery.
Renal  failure  is  highly  prevalent  in  patients  with  chronic
eart  failure;  it  could  have  an  incidence  of  up  to  25%.8
urthermore,  this  fall  in  glomerular  ﬁltration  could  worsen
orbidity  and  mortality  in  acute  heart  failure.9
There  are  few  studies  on  the  effectiveness  of  preoper-
tive  therapy  for  preventing  and  treating  the  deterioration
f  cardiac  function  in  patients  undergoing  major  surgery.7,10
rophylactic  use  of  conventional  inotropic  drugs  is  con-
roversial:  it  may  cause  an  increase  in  myocardial  oxygen
onsumption,  vasodilation  and  risk  of  arrhythmias.11
After  its  recent  introduction  in  clinical  practice,  lev-
simendan,  thanks  to  an  original  mechanism  of  action,
as  been  proved  to  be  effective  in  achieving  an  improve-
ent  in  cardiac  function  and  perfusion  of  tissues  and
o  be  associated  with  a signiﬁcant  reduction  in  mortal-
ty  in  critically  ill  patients.12 The  drug  has  been  reported
o  present  even  anti-inﬂammatory,  anti-oxidant  and  anti-
poptotic  effects.13 Levosimendan  has  showed  a  beneﬁcial
ffect  on  renal  function  in  patients  with  established  renal
ailure,  probably  because  of  the  raise  in  renal  blood  ﬂow,
ue  to  the  increased  cardiac  output,  vasodilation  and  possi-
le  anti-inﬂammatory  properties.6,14
In  the  present  case,  levosimendan  was  used  as  preop-
rative  treatment  in  order  to  optimize  cardiac  performance
nd  to  improve  renal  function  before  surgery.  The  treatment
roved  to  be  effective;  the  patient  was  successfully  with-
rawn  from  renal  replacement,  and  she  was  submitted  to
he  intervention  and  she  showed  to  possess  an  effective  car-
iac  function,  since  she  resisted  to  acute  and  huge  changes
n  intravascular  volume.
The  treatment  protocol,  recommended  by  levosimendan
nformative  sheet,  consists  in  a  loading  dose  of  2.4  mcg/kg,
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in  a  rapid  infusion  of  approximately  10  min,  followed  by  a
continuous  infusion  of  0.1  mcg/kg/min  for  24  h.  In  patients
with  acute  myocardial  failure,  the  administration  of  a  load-
ing  dose  has  been  associated  with  hypotensive  episodes,
difﬁcult  to  control  with  vasopressor  drugs.15 In  order  to
avoid  these  hypotensive  episodes  that  may  worsen,  instead
of  improving,  patient’s  prognosis,  some  authors  recommend
a  more  careful  protocol,  consisting  in  no  loading  dose  and
a  gradual  increasing  in  infusion  rate.15 In  the  present  case,
the  progressive  introduction  of  levosimendan  infusion  was
not  associated  to  hypotensive  episodes  or  an  augmenta-
tion  in  vasoconstrictors  requirement.  The  reduced  systemic
resistance  showed  only  the  beneﬁcial  face  of  the  medal,
increasing  renal  perfusion  and  improving  microcirculation.
Conclusion
Levosimendan  may  constitute  a  valid  choice  to  be  consid-
ered  in  the  management  of  preoperative  decompensated
heart  failure  associated  with  renal  insufﬁciency.  The  main
property  of  the  drug  (inotropic  and  vasodilation  positive
effects)  allowed  to  restore  renal  function  and  to  prepare  the
patient  for  the  intervention.  Moreover,  the  new  equilibrium,
between  increased  cardiac  function  and  beneﬁcial  vasodila-
tion,  was  helpful  during  and  after  intervention  because  it
allowed  the  cardiovascular  system  of  our  patient  to  deal
with  the  consequences  of  haemorrhage  and  ﬂuid  therapy.
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